Talk:Kanna: Difference between revisions
>Utaninja →Combination effects: Fixed typo |
>Brack →Pharmacology: correction of mechanism of action misinformation |
||
(9 intermediate revisions by 3 users not shown) | |||
Line 11: | Line 11: | ||
{{chemistry}} | {{chemistry}} | ||
The active compounds in kanna are mesembrine, mesembrenone, mesembrenol, and tortuosamine. It is believed that mesembrine and mesembrenone are responsible for the majority of kanna's effects. | The active compounds in kanna are mesembrine, mesembrenone, mesembrenol, and tortuosamine. It is believed that mesembrine and mesembrenone are responsible for the majority of kanna's effects. | ||
Chemistry of Kanna (Sceletium tortuosum) | |||
Kanna contains a variety of alkaloids, which are responsible for its psychoactive effects. The primary bioactive compounds are mesembrine-type alkaloids, along with other secondary metabolites. | |||
1. Mesembrine Alkaloids (Primary Active Compounds) | |||
Mesembrine – A serotonin reuptake inhibitor (SRI) and mild phosphodiesterase-4 (PDE4) inhibitor. It has a high affinity for the serotonin transporter (SERT), with a K<sub>i</sub> value of 1.4 nM, meaning it strongly inhibits serotonin reuptake. It also inhibits PDE4 at a much weaker level (K<sub>i</sub> = 7,800 nM) (Smith et al., 1998). | |||
Mesembrenone – Functions as both an SRI and a PDE4 inhibitor, though it is weaker at serotonin reuptake inhibition than mesembrine (K<sub>i</sub> = 27 nM for SERT). However, it more potently inhibits PDE4, with a K<sub>i</sub> value of 470 nM, suggesting potential anti-inflammatory and cognitive-enhancing effects (Gericke & Viljoen, 2008). | |||
Mesembrenol – A metabolite of mesembrine that is thought to contribute to Kanna’s anxiolytic and mood-enhancing effects. Specific pharmacological data on mesembrenol are limited. | |||
Tortuosamine – A lesser-known alkaloid found in Kanna. Its precise pharmacological properties are not well studied, but it is suspected to play a minor role in Kanna's psychoactive profile (PubChem). | |||
2. Additional Compounds | |||
In addition to mesembrine alkaloids, Kanna also contains: | |||
Flavonoids – Antioxidant compounds with potential neuroprotective and anti-inflammatory properties. | |||
Tannins – Polyphenolic compounds that may affect taste and bioavailability. | |||
Saponins – Plant-based glycosides with potential immune-modulating properties. | |||
[[User:Planlos69|Planlos69]] ([[User talk:Planlos69|talk]]) 09:49, 30 January 2025 (UTC) | |||
==Pharmacology== | ==Pharmacology== | ||
{{pharmacology}} | {{pharmacology}} | ||
The main psychoactive effects of kanna are a result of its action as a potent serotonin reuptake inhibitor ([[SRI]]), a [https://en.wikipedia.org/wiki/Phosphodiesterase-4_inhibitor PDE4 inhibitor], and | The main psychoactive effects of kanna are a result of its action as a potent serotonin reuptake inhibitor ([[SRI]]), a [https://en.wikipedia.org/wiki/Phosphodiesterase-4_inhibitor PDE4 inhibitor], and a monoamine releasing agent. <ref>https://www.sciencedirect.com/science/article/pii/S0378874115302348?via%3Dihub</ref>. | ||
The VMAT2 upregulation produced by kanna is a compensatory response produced by stimulants such as cocaine and methylphenidate <ref>https://pubmed.ncbi.nlm.nih.gov/16897597/</ref>. However, some online users have misinterpreted the findings of VMAT2 upregulation from kanna as evidence of being a different type of stimulant. This is false, and monoamine releasing agents upregulate VMAT2 as a compensatory mechanism, involved in tolerance. VMAT2 upregulation is evidence that a compound acts similar to monoamine releasers like cocaine and methylphenidate <ref>https://pmc.ncbi.nlm.nih.gov/articles/PMC6757793/</ref> | |||
{| class="wikitable" | {| class="wikitable" | ||
|- | |- | ||
Line 31: | Line 63: | ||
| ND || ND | | ND || ND | ||
|} | |} | ||
Pharmacology | |||
Mechanism of Action | |||
Kanna primarily works by inhibiting serotonin reuptake, increasing serotonin levels in the synaptic cleft. This leads to mood enhancement, anxiolysis, and mild euphoria. | |||
Additionally, the PDE4 inhibition by mesembrenone may contribute to neuroprotection, anti-inflammatory effects, and cognitive benefits (Lima et al., 2022). | |||
Pharmacokinetics | |||
Half-life: Not well-documented, but estimated to be 4–6 hours based on anecdotal reports. | |||
Bioavailability: | |||
Oral & sublingual: High | |||
Intranasal: Moderate | |||
Inhaled (smoked/vaporized): Low | |||
More research is needed to determine the exact metabolic pathways and elimination rates of mesembrine alkaloids in humans. | |||
[[User:Planlos69|Planlos69]] ([[User talk:Planlos69|talk]]) 09:49, 30 January 2025 (UTC) | |||
==Subjective effects== | ==Subjective effects== |